[go: up one dir, main page]

WO2006065590A3 - Pyridine and pyrimidine antiviral compositions - Google Patents

Pyridine and pyrimidine antiviral compositions Download PDF

Info

Publication number
WO2006065590A3
WO2006065590A3 PCT/US2005/044206 US2005044206W WO2006065590A3 WO 2006065590 A3 WO2006065590 A3 WO 2006065590A3 US 2005044206 W US2005044206 W US 2005044206W WO 2006065590 A3 WO2006065590 A3 WO 2006065590A3
Authority
WO
WIPO (PCT)
Prior art keywords
pyridine
antiviral compositions
pyrimidine
pyrimidine antiviral
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2005/044206
Other languages
French (fr)
Other versions
WO2006065590A2 (en
Inventor
C Richard Wobbe
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
XTL BIOPHARMACEUTICALS Inc
Original Assignee
XTL BIOPHARMACEUTICALS Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by XTL BIOPHARMACEUTICALS Inc filed Critical XTL BIOPHARMACEUTICALS Inc
Publication of WO2006065590A2 publication Critical patent/WO2006065590A2/en
Publication of WO2006065590A3 publication Critical patent/WO2006065590A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • C07D213/80—Acids; Esters in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to pyridines and pyrimidine derivatives of formula (I) wherein R1, R2, R3, R4 and R5 are as defined herein, and their pharmaceutical compositions useful as antiviral compounds, and their methods of preparation and methods for use in the treatment as antiviral agents.
PCT/US2005/044206 2004-12-16 2005-12-05 Pyridine and pyrimidine antiviral compositions Ceased WO2006065590A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63710804P 2004-12-16 2004-12-16
US60/637,108 2004-12-16

Publications (2)

Publication Number Publication Date
WO2006065590A2 WO2006065590A2 (en) 2006-06-22
WO2006065590A3 true WO2006065590A3 (en) 2006-09-21

Family

ID=36337452

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/044206 Ceased WO2006065590A2 (en) 2004-12-16 2005-12-05 Pyridine and pyrimidine antiviral compositions

Country Status (1)

Country Link
WO (1) WO2006065590A2 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8841275B2 (en) 2010-11-30 2014-09-23 Gilead Pharmasset Llc 2′-spiro-nucleosides and derivatives thereof useful for treating hepatitis C virus and dengue virus infections
US8957046B2 (en) 2007-03-30 2015-02-17 Gilead Pharmasset Llc Nucleoside phosphoramidate prodrugs
US9549941B2 (en) 2011-11-29 2017-01-24 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CL2008000467A1 (en) 2007-02-14 2008-08-22 Janssen Pharmaceutica Nv COMPOUNDS DERIVED FROM 2-AMINOPIRIMIDINE, HISTAMINE RECEIVER MODULATORS H4; YOUR PREPARATION PROCEDURE; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUNDS; AND ITS USE TO TREAT A SELECTED INFLAMMATORY DISORDER OF ALEGIA, ASMA
CN101815533A (en) 2007-05-04 2010-08-25 弗特克斯药品有限公司 Combination Therapies for the Treatment of HCV Infection
EP2326627A1 (en) 2008-08-20 2011-06-01 Schering Corporation Substituted pyridine and pyrimidine derivatives and their use in treating viral infections
WO2010022125A1 (en) 2008-08-20 2010-02-25 Schering Corporation Ethynyl-substituted pyridine and pyrimidine derivatives and their use in treating viral infections
CA2734488A1 (en) 2008-08-20 2010-02-25 Southern Research Institute Azo-substituted pyridine and pyrimidine derivatives and their use in treating viral infections
US8715638B2 (en) 2008-08-20 2014-05-06 Merck Sharp & Dohme Corp. Ethenyl-substituted pyridine and pyrimidine derivatives and their use in treating viral infections
ES2623016T3 (en) 2008-12-23 2017-07-10 Gilead Pharmasset Llc 6-O-substituted 2-amino purine nucleoside phosphoramidates
JP6104504B2 (en) 2008-12-23 2017-03-29 ギリアド ファーマセット エルエルシー Nucleoside analogues
CN102325783A (en) 2008-12-23 2012-01-18 法莫赛特股份有限公司 Synthesis of purine nucleosides
TWI598358B (en) 2009-05-20 2017-09-11 基利法瑪席特有限責任公司 Nucleoside phosphoramidates
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
PL2609923T4 (en) 2010-03-31 2017-11-30 Gilead Pharmasset Llc Process for the crystallisation of (s)-isopropyl 2-(((s)-(perfluorophenoxy)(phenoxy)phosphoryl)amino)propanoate
MX350725B (en) 2010-03-31 2017-09-14 Gilead Pharmasset Llc Nucleoside phosphoramidates.
JP2016529293A (en) 2013-08-27 2016-09-23 ギリアド ファーマセット エルエルシー Combination preparation of two antiviral compounds
CA3026149A1 (en) 2016-06-02 2017-12-07 Cadent Therapeutics, Inc. Potassium channel modulators
HUE057710T2 (en) 2017-01-23 2022-05-28 Cadent Therapeutics Inc Potassium channel modulators
US11993586B2 (en) 2018-10-22 2024-05-28 Novartis Ag Crystalline forms of potassium channel modulators
CN116507611A (en) * 2020-11-06 2023-07-28 佩勒梅德有限公司 Novel capsid assembly inhibitors

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001078648A2 (en) * 2000-04-17 2001-10-25 Dong Wha Pharm. Ind. Co., Ltd. 6-methylnicotinamide derivatives as antiviral agents
WO2003078427A1 (en) * 2002-03-15 2003-09-25 Vertex Pharmaceuticals, Inc. Azolylaminoazines as inhibitors of protein kinases
WO2003084953A1 (en) * 2002-04-04 2003-10-16 B & C Biopharm 6-(4-substituted-anilino)pyrimidine derivatives, method for the preparation thereof and antiviral pharmaceutical composition comprising the same
US20050192294A1 (en) * 2004-02-27 2005-09-01 Bayer Pharmaceuticals Corporation Heteroarylaminopyrazole derivatives useful for the treatment of diabetes

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001078648A2 (en) * 2000-04-17 2001-10-25 Dong Wha Pharm. Ind. Co., Ltd. 6-methylnicotinamide derivatives as antiviral agents
WO2003078427A1 (en) * 2002-03-15 2003-09-25 Vertex Pharmaceuticals, Inc. Azolylaminoazines as inhibitors of protein kinases
WO2003084953A1 (en) * 2002-04-04 2003-10-16 B & C Biopharm 6-(4-substituted-anilino)pyrimidine derivatives, method for the preparation thereof and antiviral pharmaceutical composition comprising the same
US20050192294A1 (en) * 2004-02-27 2005-09-01 Bayer Pharmaceuticals Corporation Heteroarylaminopyrazole derivatives useful for the treatment of diabetes

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ROUCHAUD, J. ET AL: "Soil metabolism of flupyrsulfuron in winter wheat crops", WEED RESEARCH , 42(1), 14-25 CODEN: WEREAT; ISSN: 0043-1737, 2002, XP002383028 *
ROUCHAUD, JEAN ET AL: "Flupyrsulfuron Soil Dissipation and Mobility in Winter Wheat Crops", JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY , 47(9), 3872-3878 CODEN: JAFCAU; ISSN: 0021-8561, 1999, XP002383029 *
ROUCHAUD, JEAN ET AL: "The cyclization transformation of the sulfonylurea herbicide flupyrsulfuron in the soil of winter wheat crops", PEST MANAGEMENT SCIENCE , 59(8), 940-948 CODEN: PMSCFC; ISSN: 1526-498X, 2003, XP002383027 *
SINGLES, SUZANNE KOCH ET AL: "Fate and behavior of flupyrsulfuron-methyl in soil and aquatic systems", PESTICIDE SCIENCE , 55(3), 288-300 CODEN: PSSCBG; ISSN: 0031-613X, 1999, XP002383030 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8957046B2 (en) 2007-03-30 2015-02-17 Gilead Pharmasset Llc Nucleoside phosphoramidate prodrugs
US8841275B2 (en) 2010-11-30 2014-09-23 Gilead Pharmasset Llc 2′-spiro-nucleosides and derivatives thereof useful for treating hepatitis C virus and dengue virus infections
US9549941B2 (en) 2011-11-29 2017-01-24 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus

Also Published As

Publication number Publication date
WO2006065590A2 (en) 2006-06-22

Similar Documents

Publication Publication Date Title
WO2006065590A3 (en) Pyridine and pyrimidine antiviral compositions
WO2005123731A3 (en) Pyrrolopyridine derivatives and their use as crth2 antagonists
WO2006011050A3 (en) Pyridine derivatives
WO2006021454A3 (en) Pyrimidine derivatives
WO2005110994A8 (en) Substituted pyrazolyl urea derivatives useful in the treatment of cancer
NO20091394L (en) Pyridin-4-yl derivatives as immunomodulatory agents
PH12012501817A1 (en) Polysubstituted derivatives of 6-heteroaryl-imidazo[1,2-a] pyridines, and preparation and therapeutic use thereof
TW200732323A (en) Organic compounds
TNSN07074A1 (en) Pyrimidine derivatives
WO2007090141A3 (en) Pyrrolo [2, 3, b] pyridine derivatives useful as raf kinase inhibitors
NO20070339L (en) 1-aza-bicyclo [3 3.1] nonanes
IL185611A0 (en) Novel imidazo[1,5-a]pyridine derivatives, method for preparing same and pharmaceutical compositions containing same
TW200606162A (en) Pyrazolopyridine derivatives
GEP20135780B (en) Novel pyrazolo [3,4-d] pyrimidine derivatives as anti-cancer agents
WO2006126082A3 (en) Pyridine [3,4-b] pyrazinones as pde-5 inhibitors
WO2009016498A8 (en) Pyrimidine and pyridine derivatives and their pharmaceutical use and compositions
WO2007044724A3 (en) Aminopyrimidine, aminopyridine and aniline derivatives inhibitors of pim-i and/or pim-3
MX2007007098A (en) Pyrrole derivatives having crth2 receptor antagonist activity.
MY183039A (en) Pyridin-2-yl derivatives as immunomodulating agents
NO20080418L (en) Pyrido [2,3-D] pyrimidiride derivatives, process for their preparation and therapeutic use of the same
WO2008104473A3 (en) Pyrazolopyriidine derivatives and their use as kinase inhibitors
MX2007008237A (en) Novel pyridine compounds.
WO2006010591A3 (en) Quinazoline derivatives
WO2005009965A8 (en) Nicotinamide derivatives useful as pde4 inhibitors
DK1869038T3 (en) Substituted 5,6,7,8-tetrahydro-imidazole [1,2-a] pyridin-2-ylamine compounds and their use in the manufacture of drugs

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KN KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS FF RIGHTS PURSUANT TO RULE 112(1) EPC

122 Ep: pct application non-entry in european phase

Ref document number: 05853195

Country of ref document: EP

Kind code of ref document: A2